BLFS icon

BioLife Solutions

21.15 USD
-0.76
3.47%
At close Apr 21, 4:00 PM EDT
After hours
21.15
+0.00
0.00%
1 day
-3.47%
5 days
-5.50%
1 month
-15.37%
3 months
-23.03%
6 months
-8.08%
Year to date
-19.21%
1 year
25.89%
5 years
99.72%
10 years
947.03%
 

About: BioLife Solutions Inc is a life sciences company that develops, manufactures, and markets bioproduction products and services that are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. The company provides solutions such as Cell Processing, Cold Chain, and Thawing. The company generates the majority of its revenue from Cell Processing through the biopreservation product "CryoStor". Geographically the company generates the majority of its revenue from the United States.

Employees: 159

0
Funds holding %
of 7,419 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

14% more repeat investments, than reductions

Existing positions increased: 66 | Existing positions reduced: 58

7% more capital invested

Capital invested by funds: $1.13B [Q3] → $1.21B (+$83.1M) [Q4]

2.95% more ownership

Funds ownership: 97.93% [Q3] → 100.88% (+2.95%) [Q4]

0% more funds holding in top 10

Funds holding in top 10: 3 [Q3] → 3 (+0) [Q4]

7% less funds holding

Funds holding: 193 [Q3] → 179 (-14) [Q4]

33% less first-time investments, than exits

New positions opened: 22 | Existing positions closed: 33

34% less call options, than puts

Call options by funds: $122K | Put options by funds: $184K

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target
$30
42%
upside
Avg. target
$30
42%
upside
High target
$30
42%
upside

1 analyst rating

positive
100%
neutral
0%
negative
0%
HC Wainwright & Co.
Yi Chen
28% 1-year accuracy
48 / 172 met price target
42%upside
$30
Buy
Maintained
6 Mar 2025

Financial journalist opinion

Based on 3 articles about BLFS published over the past 30 days

Neutral
PRNewsWire
2 weeks ago
BioLife Solutions Acquires PanTHERA CryoSolutions to Advance Leadership as a Pure Play Bioproduction Consumables Company
Strategic acquisition enhances biopreservation media portfolio with novel Ice Recrystallization Inhibitor technology Marks the second acquisition from Bioproduction Innovation Accelerator program BOTHELL, Wash. , April 7, 2025 /PRNewswire/ --  BioLife Solutions , Inc. (NASDAQ: BLFS ) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") market, today announced the acquisition of privately-held PanTHERA CryoSolutions, Inc., ("PanTHERA"), a developer of novel cryopreservation solutions based on proprietary Ice Recrystallization Inhibitor ("IRI") technology.
BioLife Solutions Acquires PanTHERA CryoSolutions to Advance Leadership as a Pure Play Bioproduction Consumables Company
Positive
Seeking Alpha
2 weeks ago
BioLife Solutions: A Steady Stock Lined Up For Success In A Booming Industry
BioLife Solutions, an established biotech firm, is poised to benefit from the booming cell and gene therapy sector, projected to grow significantly by 2030. Despite recent negative EPS, BioLife has consistently exceeded earnings expectations, indicating strong future potential and investor confidence. BioLife's unique focus on cell preservation and storage positions it advantageously within the CGT sector, with expected revenue growth heavily outpacing peers.
BioLife Solutions: A Steady Stock Lined Up For Success In A Booming Industry
Positive
Zacks Investment Research
4 weeks ago
5 Low-Leverage Stocks to Buy Amid Trump's Tariff Woes
The majority of U.S. stock indices ended barely in the green on March 21, 2025, overcoming their recent losing streaks since investors remain wary about the long-term economic impacts of President Trump's enhanced import tariffs. The latest uptick in the major stock indices was mostly because the Federal Reserve kept its projection for interest rate cuts broadly unchanged, indicating economic stability for the time being.
5 Low-Leverage Stocks to Buy Amid Trump's Tariff Woes
Neutral
PRNewsWire
1 month ago
BioLife Solutions Appoints Cathy Coste as Director and Audit Committee Chair
BOTHELL, Wash. , March 18, 2025 /PRNewswire/ -- BioLife Solutions , Inc. (Nasdaq: BLFS ) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction tools and services for the cell and gene therapy (CGT) market, announces the appointment of Cathy Coste to its board of directors, increasing board membership to seven.
BioLife Solutions Appoints Cathy Coste as Director and Audit Committee Chair
Positive
Zacks Investment Research
1 month ago
5 Low-Leverage Stocks to Buy Amid Volatile Market Sentiment
The crux of safe investment lies in choosing a company that is not burdened with debt. You may buy BLFS, BHLB, NVDA, GBX and EZPW.
5 Low-Leverage Stocks to Buy Amid Volatile Market Sentiment
Neutral
Seeking Alpha
1 month ago
BioLife Solutions, Inc. (BLFS) Q4 2024 Earnings Call Transcript
BioLife Solutions, Inc. (BLFS) Q4 2024 Earnings Call Transcript
BioLife Solutions, Inc. (BLFS) Q4 2024 Earnings Call Transcript
Negative
Zacks Investment Research
1 month ago
BioLife Solutions, Inc. (BLFS) Reports Q4 Loss, Tops Revenue Estimates
BioLife Solutions, Inc. (BLFS) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to loss of $0.30 per share a year ago.
BioLife Solutions, Inc. (BLFS) Reports Q4 Loss, Tops Revenue Estimates
Neutral
PRNewsWire
1 month ago
BioLife Solutions Reports Fourth Quarter and Full Year 2024 Financial Results
Cell Processing revenue up 7%  sequentially to $20.3 million in the fourth quarter; 2024 Cell Processing revenue up 12%  over prior year to $73.5 million GAAP gross margin of 60%  and non-GAAP adjusted gross margin of 63%  for the fourth quarter GAAP net loss from continuing operations of $2.0 million and non-GAAP adjusted EBITDA of $4.0 million, or 18%  of total revenue for the fourth quarter Expects 2025  Cell Processing revenue of $86.5 to $89.0 million, up 18%  to 21%  over 2024 and total revenue of $95.5 to $99.0 million, up 16%  to 20%  over 2024 Conference call begins at 8:00 a.m. Eastern time today  BOTHELL, Wash.
BioLife Solutions Reports Fourth Quarter and Full Year 2024 Financial Results
Neutral
PRNewsWire
1 month ago
BioLife Solutions to Report Fourth Quarter and Full Year 2024 Financial Results and Business Update on March 3, 2025
BOTHELL, Wash. , Feb. 20, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") market, today announced the 2024 fourth quarter and full year financial results will be released on March 3, 2025 pre-market.
BioLife Solutions to Report Fourth Quarter and Full Year 2024 Financial Results and Business Update on March 3, 2025
Positive
Zacks Investment Research
2 months ago
Recent Price Trend in BioLife Solutions (BLFS) is Your Friend, Here's Why
BioLife Solutions (BLFS) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Recent Price Trend in BioLife Solutions (BLFS) is Your Friend, Here's Why
Charts implemented using Lightweight Charts™